OraSure appoints Nancy Gagliano and Anne Whitaker to board of directors

ORASURE TECHNOLOGIES INC

Board increased from nine to ten members; appointments effective November 8, 2021.
Dr. Gagliano brings experience from NIH RADx program and CVS Health; will serve on Nominating & Corp Governance Committee.
Ms. Whitaker brings pharma executive and public board experience; will serve on Audit Committee.
Each received initial equity award of $105,000 in restricted shares vesting over two years.
Both directors are independent under Nasdaq listing rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nancy J. Gagliano

Director

OSUR · ORASURE TECHNOLOGIES INC

Effective: 2021-11-07
Filed: November 8, 2021, 6:59 PM ET

the Board appointed Nancy J. Gagliano, M.D. and Anne C. Whitaker as new members of the Board.

Appointed

Anne C. Whitaker

Director

OSUR · ORASURE TECHNOLOGIES INC

Effective: 2021-11-07
Filed: November 8, 2021, 6:59 PM ET

the Board appointed Nancy J. Gagliano, M.D. and Anne C. Whitaker as new members of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy J. Gagliano was appointed as Director at ORASURE TECHNOLOGIES INC.

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Nancy J. Gagliano, M.D. and Anne C. Whitaker as new members of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anne C. Whitaker was appointed as Director at ORASURE TECHNOLOGIES INC.

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Nancy J. Gagliano, M.D. and Anne C. Whitaker as new members of the Board.

View on SEC.gov

ORASURE TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0000950170-21-003312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.